AxoGen

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AxoGen reports robust Q4 earnings, eyes growth through innovation

AxoGen's Q4 2022 performance showcased revenue growth, strong margins, and a focus on market expansion through core accounts.
The company's strengths lie in innovative products, high surgeon adoption rates, and a clear roadmap for future growth.
Challenges include post-COVID segment recovery, referral process acceleration, and balancing expenses with revenue.
Opportunities in rep productivity enhancement, product innovation, and regulatory milestones position AxoGen for continued success and market leadership.

AxoGen reports robust Q1 revenue growth and innovation focus

AxoGen's Q1 performance reflects strong revenue growth and market penetration strategies, supported by innovative product introductions and a clear outlook for future revenue and margin improvements.
While facing challenges in managing expenses and executing facility transitions, AxoGen's focus on niche market segments and commitment to R&D present opportunities for sustained growth and profitability.
Overall, AxoGen's strategic direction, emphasis on product innovation, and dedication to improving patient outcomes position the company well for long-term success and market expansion.

AxoGen reports revenue growth and product expansion in Q2

AxoGen's Q2 performance showed revenue growth, increased active accounts, and new product introductions.
Strengths include focus on Core Accounts, sales efforts, and no supply challenges affecting production.
Challenges include validation delay impacting gross margin and extended BLA submission timeline.
Opportunities lie in upcoming product launches, growth in scheduled procedures, and commitment to patient outcomes.

AxoGen reports robust Q3 growth driven by innovative nerve solutions

AxoGen's Q3 performance reflects strong revenue growth driven by emergent trauma and scheduled procedures, supported by a focus on core accounts and innovative products.
While challenges like a net loss persist, opportunities lie in market expansion, regulatory approvals, and maintaining revenue guidance, positioning the company for future success.
Investors should monitor AxoGen's ability to manage expenses, achieve profitability, and leverage its product innovations to drive sustainable growth and shareholder value.

AxoGen reports robust revenue growth, addresses supply chain challenges

AxoGen's strong revenue growth and product innovation demonstrate resilience and market potential.
While challenges like supply chain disruptions persist, the company's focus on cost management and customer relationships is key.
Opportunities lie in market expansion through new products and sustained revenue growth in the coming year.
Analysts are optimistic about AxoGen's performance and strategic direction, emphasizing the need for operational efficiency.

AxoGen reports revenue growth and innovation drive amidst challenges

AxoGen's Q1 2024 performance reflects revenue growth and strategic focus on core accounts and innovation. While challenges like net losses persist, opportunities lie in upcoming product approvals and enhanced transparency. The company's maintained full-year guidance indicates a positive outlook for revenue and cash flow.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ALACHUA, Fla., July  15, 2020  (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report second quarter 2020 financial results on Wednesday, August 5, 2020 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.

Axogen, Inc. to Report Second Quarter 2020 Financial Results and Host Conference Call on August 5, 2020

ALACHUA, Fla., July  01, 2020  (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced a financing agreement with Oberland Capital and provided preliminary, estimated revenue for the second quarter ended June 30, 2020.

Axogen Announces New Seven-Year Financing Agreement with Oberland Capital and Provides Preliminary Second Quarter Revenue Estimate

Freitag will continue as member of board of directors and serve as special counsel in transitional role through October Freitag will continue as member of board of directors and serve as special counsel in transitional role through October

Axogen, Inc. Announces Planned Retirement of Greg Freitag and Appoints Brad Ottinger as General Counsel and Chief Compliance Officer

ALACHUA, Fla., May  20, 2020  (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Jefferies Virtual Healthcare Conference. The presentation is scheduled for Wednesday, June 3, 2020 at 2:00 p.m. ET.

Axogen, Inc. to Present at the Jefferies Virtual Healthcare Conference

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2020 Results - Earnings Call Transcript

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AxoGen (AXGN) Q1 Earnings Expected to Decline

ALACHUA, Fla., April  23, 2020  (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary first quarter 2020 revenue, provided a business update on its actions in response to the COVID-19 pandemic, and announced the dismissal of its class-action lawsuit.

Axogen, Inc. Reports Preliminary Revenue for the First Quarter 2020, Provides Business Update in Response to COVID-19 Pandemic, and Announces Dismissal of Class Action Lawsuit

ALACHUA, Fla., March  02, 2020  (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that members of its management team will participate in two investor conferences during March.

Axogen, Inc. to Participate at Upcoming  Investor Conferences

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2019 Results - Earnings Call Transcript

Largest peripheral nerve repair registry in the world generates clinical evidence of repair, safety, and outcomes data for peripheral nerve injuries Largest peripheral nerve repair registry in the world generates clinical evidence of repair, safety, and outcomes data for peripheral nerve injuries

Axogen Sponsored RANGER® Registry Reaches 2,000 Nerve Repair Enrollment Milestone

AxoGen Working Its Way Out Of The Penalty Box, But Execution Is Key

Company will develop an automated bioprocessing system for human tissue scaffolds

Axogen awarded research grant from the Advanced Regenerative Manufacturing Institute

Parade float will highlight the life-changing power of tissue and organ donation Parade float will highlight the life-changing power of tissue and organ donation

Avance® Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade® Float

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q3 2019 Results - Earnings Call Transcript

Earnings Preview: AxoGen (AXGN) Q3 Earnings Expected to Decline

ALACHUA, Fla., Sept.  19, 2019  (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, chief executive officer, and president, will present at the Cantor Fitzgerald Global Healthcare Conference in New York City. The presentation is scheduled for October 2, 2019 at 1:15 p.m. ET.

Axogen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

Updated outcomes data from the RANGER ®  Registry’s  MATCH SM  cohort  will be presented during scientific sessions

Axogen to Participate in the 74th Annual  American Society for Surgery of the Hand Meeting

Capri Holdings Ltd

General Electric

Ryman Hospitality Properties

Sarepta Therapeutics

Insiders invest in Capri Holdings, General Electric, Sarepta Therapeutics, Ryman Hospitality Properties and Axogen.

Weekly CEO Buys Highlight

CEO of Axogen Inc (30-Year Financial, Insider Trades) Karen L. Zaderej (insider trades) bought 75,000 shares of AXGN on 08/09/2019 at an average price of $13.5 a share.

Axogen Inc (AXGN) CEO Karen L. Zaderej Bought $1 million of Shares

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q2 2019 Results - Earnings Call Transcript

AxoGen (AXGN) delivered earnings and revenue surprises of 23.08% and -0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Reports Q2 Loss, Misses Revenue Estimates

Amidst worries about market size, competition, trial design, and executive turnover, AxoGen has also suffered from a rotation away from growth med-tech that had propelled sector multiples to long-term highs.

The Street Still Highly Skeptical On AxoGen's Growth Story

Evolent Health

Axogen, Evolent Health present appealing opportunities.

Analysts Recommend These 2 Falling Knives.

AxoGen's (AXGN) CEO Karen Zaderej on Q1 2019 Results - Earnings Call Transcript

News for AxoGen Stock (AXGN)